Synopsys said revenues for the 3 months ended January 31, 2025 were $1.5 billion, a decrease of $55.7 million or 4%. The company cited the impact of an extra 1 weeks in Q1 2024 of approximately $63.2 million and a decrease in IP and hardware revenue of approximately $74.0 million as factors.

1. 01

   Synopsys said revenues for the 3 months ended January 31, 2025 were $1.5 billion, a decrease of $55.7 million or 4%. The company cited the impact of an extra 1 weeks in Q1 2024 of approximately $63.2 million and a decrease in IP and hardware revenue of approximately $74.0 million as factors.

2. 02

   Synopsys said total cost of revenue and operating expenses for the 3 months ended January 31, 2025 were $1.2 billion, an increase of $45.1 million or 4%. The company cited an increase of $34.4 million in legal, consulting and other professional fees in connection with the Ansys Merger and $27.1 million in employee-related costs from headcount increases as factors.

3. 03

   Synopsys said it is proceeding with a merger in which it will pay Ansys shareholders 0.3450 shares of Synopsys common stock and $197.00 in cash per Ansys share, and plans to fund approximately $19 billion in cash consideration through a combination of cash and debt. The company said it has fully-committed debt financing of $14.9 billion (including $10.6 billion under the Bridge Commitment).

4. 04

   Synopsys said as of January 31, 2025 it held $3.8 billion in cash, cash equivalents and short-term investments. The company said $194.3 million remained available for future stock repurchases under its stock repurchase program, but it has suspended the program in connection with the pending Ansys Merger.

Key figures

Quarter ended January 31, 2025

Revenue

$1.5B

Operating income

$252M

Net income

$296M

EPS

$1.89

Gross profit

$1.2B

Operating cash flow

−$67M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.